A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

Schwarze, J. K. (Speaker), Vanbinst, A. (Contributor)

Activity: Talk or presentationTalk or presentation at a conference

Period2020 → …
Event typeConference